TISIDB

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Nucleus
Domain	PF00389 D-isomer specific 2-hydroxyacid dehydrogenase PF02826 D-isomer specific 2-hydroxyacid dehydrogenase
Function	Corepressor targeting diverse transcription regulators such as GLIS2 or BCL6. Has dehydrogenase activity. Involved in controlling the equilibrium between tubular and stacked structures in the Golgi complex. Functions in brown adipose tissue (BAT) differentiation.

> Gene Ontology [ TOP ]
Biological Process	GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0006476 protein deacetylation GO:0016570 histone modification GO:0016573 histone acetylation GO:0016575 histone deacetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0019058 viral life cycle GO:0019079 viral genome replication GO:0031056 regulation of histone modification GO:0031057 negative regulation of histone modification GO:0031058 positive regulation of histone modification GO:0031063 regulation of histone deacetylation GO:0031065 positive regulation of histone deacetylation GO:0035065 regulation of histone acetylation GO:0035067 negative regulation of histone acetylation GO:0035601 protein deacylation GO:0043543 protein acylation GO:0043967 histone H4 acetylation GO:0045444 fat cell differentiation GO:0050872 white fat cell differentiation GO:0090239 regulation of histone H4 acetylation GO:0090241 negative regulation of histone H4 acetylation GO:0090311 regulation of protein deacetylation GO:0090312 positive regulation of protein deacetylation GO:0098732 macromolecule deacylation GO:1901983 regulation of protein acetylation GO:1901984 negative regulation of protein acetylation GO:1902275 regulation of chromatin organization GO:1903756 regulation of transcription from RNA polymerase II promoter by histone modification GO:1903758 negative regulation of transcription from RNA polymerase II promoter by histone modification GO:1905268 negative regulation of chromatin organization GO:1905269 positive regulation of chromatin organization GO:2000756 regulation of peptidyl-lysine acetylation GO:2000757 negative regulation of peptidyl-lysine acetylation
Molecular Function	GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001104 RNA polymerase II transcription cofactor activity GO:0001106 RNA polymerase II transcription corepressor activity GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0003714 transcription corepressor activity GO:0008022 protein C-terminus binding GO:0008134 transcription factor binding GO:0016614 oxidoreductase activity, acting on CH-OH group of donors GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0048037 cofactor binding GO:0050662 coenzyme binding GO:0051287 NAD binding GO:0070491 repressing transcription factor binding
Cellular Component	GO:0005667 transcription factor complex GO:0017053 transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04310 Wnt signaling pathway hsa04330 Notch signaling pathway
Reactome	R-HSA-3769402: Deactivation of the beta-catenin transactivating complex R-HSA-195253: Degradation of beta-catenin by the destruction complex R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-4641265: Repression of WNT target genes R-HSA-162582: Signal Transduction R-HSA-4791275: Signaling by WNT in cancer R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT R-HSA-5339700: TCF7L2 mutants don't bind CTBP

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04310 Wnt signaling pathway
hsa04330 Notch signaling pathway

Reactome

R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-195253: Degradation of beta-catenin by the destruction complex
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-4641265: Repression of WNT target genes
R-HSA-162582: Signal Transduction
R-HSA-4791275: Signaling by WNT in cancer
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-5339700: TCF7L2 mutants don't bind CTBP

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CTBP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CTBP1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.55	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CTBP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.052	0.862
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.053	0.984
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.12	0.952
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.427	0.336
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.269	0.909
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.632	0.842
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.191	0.621
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.129	0.937
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.301	0.873
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.837	0.629
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.222	0.639
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.002	0.98

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CTBP1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	20	0.294

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CTBP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CTBP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CTBP1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CTBP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CTBP1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CTBP1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CTBP1
Name	C-terminal binding protein 1
Aliases	BARS; brefeldin A-ribosylated substrate; C-terminal-binding protein 1
Chromosomal Location	4p16
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CTBP1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CTBP1.

ID	Name	Drug Type	Targets	#Targets
DB01942	Formic Acid	Small Molecule	ACYP2, CA2, CASK, CTBP1, CYTH2, FGF1, GGACT, GPHN, HMOX1, NOS1, PV ......	12

Browse CTBP1